CHARM Therapeutics

Based in London, CHARM Therapeutics is an artificial intelligence-driven biotechnology company that utilizes proprietary 3D deep-learning technology to discover and develop novel oncology drugs. The firm leverages its DragonFold platform for rapid protein and ligand co-folding to design targeted therapies, with a primary clinical focus on next-generation menin inhibitors for acute myeloid leukemia. The enterprise, which grew to approximately 60 employees by late 2023, has raised a total of $130 million in equity financing, including a $50 million Series A round at a $100 million to $150 million post-money valuation and an $80 million Series B round in 2025. This capital was secured from a syndicate of prominent lead investors that includes Nvidia, OrbiMed, Khosla Ventures, and New Enterprise Associates. CHARM Therapeutics was founded in 2021 by Laksh Aithani and Nobel laureate David Baker.

High-Level Overview

CHARM Therapeutics is a biotechnology company founded in 2021, specializing in AI-driven drug discovery for small-molecule medicines targeting challenging diseases like cancer.[1][4] It develops next-generation menin inhibitors for acute myeloid leukemia (AML), using its proprietary DragonFold platform—a 3D deep learning technology that models protein-ligand interactions to design potent, resistance-overcoming drugs.[1][3][4] The company serves the healthcare sector by addressing unmet needs in oncology, particularly for patients with poor prognoses from aggressive blood cancers.[1][3] With $82.7M raised across Series A and A-II rounds (latest in 2022, plus NVIDIA investment in 2023), CHARM is advancing its lead candidate into clinical trials in early 2026, showing strong momentum in the AI-biotech space.[1][2]

Origin Story

CHARM Therapeutics emerged in 2021 from the expertise of founders with proven backgrounds in AI and drug discovery.[1][4][5] Headquartered in London at 7 Pancras Square, the company was established to leverage cutting-edge computational tools for biotech challenges.[1] A pivotal moment came with the development of DragonFold, enabling precise small-molecule design for hard-to-drug targets.[1][3] Early traction included a $50M Series A in 2022, followed by $80M Series B (noted in recent reports), an undisclosed NVIDIA investment in 2023, and collaborations like one with Bristol Myers Squibb, fueling rapid progress toward clinic-ready assets.[1][2]

Core Differentiators

CHARM stands out in biotech through its integration of AI with targeted drug design:

• DragonFold platform: Proprietary 3D deep learning for protein-ligand co-folding, enabling discovery of small-molecule inhibitors for tough targets like menin in AML.[1][3]
• Resistance-proof menin inhibitors: Next-generation molecules that bind precisely in the KMT2A interface, retaining potency against all known clinical resistance mutations, unlike first-generation therapies.[3][4]
• High-quality candidates: Lead asset shows robust preclinical tumor regression, low predicted human doses, no QTc risks, and minimal drug-drug interactions.[3]
• AI-drug discovery focus: Combines computational speed with structural optimization for oncology, positioning CHARM at the forefront of AI-enabled small-molecule innovation.[1][2][4]

Role in the Broader Tech Landscape

CHARM rides the wave of AI in drug discovery, where deep learning accelerates small-molecule development amid rising chronic disease prevalence and R&D investments.[1][2] Timing is ideal: AML's high unmet need—aggressive progression, toxicity from current therapies, and resistance issues—aligns with booming interest in menin inhibitors, a promising class for blood cancers.[2][3][4] Market forces like growing VC for European biotechs, AI infrastructure from partners like NVIDIA, and trends in targeted therapies (e.g., biomarker-driven discovery) favor CHARM.[1][2] It influences the ecosystem by validating AI platforms like DragonFold for "undruggable" targets, potentially reshaping oncology pipelines and inspiring hybrid AI-biotech models.[1][3]

Quick Take & Future Outlook

CHARM's near-term milestone is initiating clinical trials for its lead menin inhibitor in early 2026, with potential for deeper, durable AML responses if preclinical efficacy translates.[3] Trends like AI optimization, sustainable chemistry, and menin inhibitor enthusiasm will propel it, alongside partnerships expanding its reach.[2][3] Influence may grow via successful Series B deployment, more collaborations, and DragonFold applications beyond AML, solidifying CHARM as a leader in AI-driven precision oncology—transforming "challenging targets" from barriers to breakthroughs.[1][4]